Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INSMNASDAQ:ITCINASDAQ:SMMTNASDAQ:TPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSMInsmed$69.21+4.3%$69.77$53.69▼$84.91$12.61B0.842.17 million shs1.84 million shsITCIIntra-Cellular Therapies$131.87$131.86$65.15▼$131.98$14.05B0.691.53 million shsN/ASMMTSummit Therapeutics$26.21+0.7%$23.47$2.64▼$36.91$19.47B-0.943.81 million shs2.14 million shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSMInsmed+4.29%+4.61%-3.07%-15.13%+29.24%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+2.86%+98.18%SMMTSummit Therapeutics+0.65%+1.71%+10.97%+26.68%+793.02%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSMInsmed4.3179 of 5 stars4.51.00.04.32.91.70.6ITCIIntra-Cellular Therapies0.6726 of 5 stars1.10.00.04.50.01.70.6SMMTSummit Therapeutics3.0988 of 5 stars4.53.00.00.02.61.70.0TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSMInsmed 3.00Buy$96.7339.77% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideSMMTSummit Therapeutics 3.09Buy$37.4042.69% UpsideTPTXTurning Point Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TPTX, SMMT, INSM, and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$105.005/12/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.005/9/2025INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $109.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.004/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/23/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/22/2025INSMInsmedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSMInsmed$381.03M33.08N/AN/A($2.32) per share-29.83ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44SMMTSummit Therapeutics$700K27,807.54N/AN/A$0.11 per share238.27TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSMInsmed-$749.57M-$5.95N/AN/AN/A-251.24%-4,773.73%-54.58%8/14/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ASMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest TPTX, SMMT, INSM, and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSMInsmedN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSMInsmed2.036.375.99ITCIIntra-Cellular TherapiesN/A7.667.51SMMTSummit TherapeuticsN/A8.318.31TPTXTurning Point TherapeuticsN/A16.8316.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSMInsmedN/AITCIIntra-Cellular Therapies92.33%SMMTSummit Therapeutics4.61%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipINSMInsmed3.00%ITCIIntra-Cellular Therapies2.60%SMMTSummit Therapeutics84.90%TPTXTurning Point Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSMInsmed373182.14 million170.67 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableTPTX, SMMT, INSM, and ITCI HeadlinesRecent News About These CompaniesBMS sets up Roche, Pfizer rivalry with Turning Point takeoverMay 20, 2025 | pharmaphorum.comDigging Into Turning Point USA’s Role in the Trump 2024 Ground GameOctober 8, 2024 | talkingpointsmemo.comTurning Point of Tampa Now In-Network with Blue Cross Blue Shield InsuranceSeptember 29, 2024 | markets.businessinsider.comDigital therapeutics at a turning point: What we heard at DTx EastSeptember 14, 2024 | pharmaphorum.comPTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comGlass System in Turning Point ResidenceApril 2, 2024 | archdaily.comBid to remove prosecutors sets up turning point in Trump’s Georgia caseFebruary 19, 2024 | politico.comTurning Point Brands Inc.February 17, 2024 | wsj.comAlzheimer’s: A Turning Point?February 12, 2024 | bbc.co.ukTurning Point Brands Inc (TPB)February 10, 2024 | investing.comCormorant Asset Management, LP's Net WorthFebruary 10, 2024 | benzinga.comSolving quadratic equations - EdexcelJanuary 15, 2024 | bbc.co.ukCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 19, 2023 | morningstar.comTurning Point USA: Are conservatives fighting back on campus?December 16, 2023 | bbc.comBMS bet looking good as Augtyro approved in ROS1-positive NSCLCNovember 16, 2023 | thepharmaletter.comPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodOctober 29, 2023 | ulster.ac.ukA Turning Point for Japan-US Climate Cooperation?October 28, 2023 | thediplomat.comWhat to know about the Turning Point USA incident on Arizona State University's campusOctober 28, 2023 | azcentral.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPTX, SMMT, INSM, and ITCI Company DescriptionsInsmed NASDAQ:INSM$69.21 +2.85 (+4.29%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$69.22 +0.01 (+0.01%) As of 05/29/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Summit Therapeutics NASDAQ:SMMT$26.21 +0.17 (+0.65%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$26.20 -0.01 (-0.04%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Turning Point Therapeutics NASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
